Answered You can buy a ready-made answer or pick a professional tutor to order an original one.
Case 1 A 20-year-old woman comes in concerned that she has genital herpes as she has been having unprotected sex. She does not have any lesions but wants to be tested. An antibody test is done and
Case 1
A 20-year-old woman comes in concerned that she has genital herpes as she has been having unprotected sex. She does not have any lesions but wants to be tested.
An antibody test is done and the results revealed the following:
HSV 1 IgG type-specific antibody: < 0.90 (negative)
HSV 2 IgG type-specific antibody: > 1.10 (positive)
- How would you explain these results to her?
- Can you tell if this is a recent or past infection?
- Can you tell how long ago she was infected?
Case 2
Mr. Jones, a 45-year-old man, is concerned that he has HIV as he had unprotected receptive anal sex with a man.
Answer the following questions.
- Which HIV test would be conducted first?
- If he contracted HIV, how many days after exposure would be needed before the test would be positive?
- Would you consider offering him PEP or PrEP, and if so, why and when?
Submission Details:
- Title your document with the case study completed.
- Submit your document to the Submissions Area by the due date assigned.
- Save your document as W2_CaseStudy_Lastname_Firstname.doc.
- @
- 3758 orders completed
- ANSWER
-
Tutor has posted answer for $10.00. See answer's preview
********************************************************************************************************* *** *** ABOVE TO ******** *** ************ ******** ****** Simplex ***** *** ********** NameDepartment *** Institution ********** ***** *** Course ************** NameDue DateCase ******** ****** ******* ***** *** HIVCase ***** 1The etiological agent *********** for *** ******* ** the ****** ******* virus ***** ***** ** classified **** *** **** ********** and ***** ********** providers *** diagnose ** ******* herpes *********** ********* * ****** of fluid ******** **** * blister ** *** ******** of *** ********* blood *** *** ******** ** antibodies ******** ** *** ****** ******* ***** (Ashley-Morrow ** al ***** Herpes ******* ***** type * (HSV-1) ** *********** *** the *********** ** **** ***** *** ******** ** ******* other than the ******* **** ** ********* by ************* ** al ****** Conversely ****** ******* ***** **** * ******* ** ********** *********** **** ** the genital ****** ** **** **** *** **************** ** ************** ***** *** **** she ********* positive ****** for ***** IgG ****** 110) but a ******** ****** *** ***** IgG ****** 090) ********** *** ******* ** ***** ********* ***** she *** *** have this ******** ** ***************** ** ** ***** *** ********* positive HSV-2 ****** *** ** attributed ** her ********** ** ********* sexual *************** ** Past ********* *** results ******** a potential infection **** ***** the virus commonly ********** with ******* herpes *** primarily *********** ******* sexual ******* The ********* detection ** * recent ********* ****** be conclusively *********** ***** solely ** *** ******** ** *** ********* test (Wald & ************* 2002) **** ***** the ******* ********* *** ******* up *** ********** can ****** ******* ** the **** for * ********************** ** infection *** IgG antibody **** **** *** ***** **** regarding *** ****** ** time an ********** *** been ******* ** *** ***** *** ******* ******** *** ******** ** ****** ******* ***** type 2 **************** immunoglobulin * (IgG) antibodies as ********* ** * positive ****** *** HSV * glycoprotein G ** *** ********* ** Wald *** Ashley-Morrow (2002) ***** ********** with HSV-2 ********** *** ********** of *** ************** ********* **** ** ******* exposure to the ****** ******* virus **** * ********** *** * result of ******** exposure ****** **** ** active ********* G(IgG) ********** on *** ***** **** ****** pinpoint ******* **** ** ********* occurredCase ***** ****** **** *** HIVThe ******* ********** ********* ******** ******** *** ********* *** ******** ** *** is *** HIV ******** Test ******** to ******** ********** ******** to the *** ***** The ********** procedure ** ******** ** ***** ***** as the *** ***** **** or *** ************* Immunosorbent ***** ******* test *** *** ******** **** ** designed ** ****** the ********* ** ********** and ** ***** ****** ******** outcomes ****** a ***** ********* ******* from * *** ******* ** * *** **** ******** et ** *********** ** *** Test ** ** ******* ** ********** ************* ****** period *** ******** testing after potential *** exposure *** unprotected receptive anal *** Although some ***** can detect *** antibodies within a few ***** waiting ** ***** *** ** **** ***** after ******** ** ********* ************** **** ******** and ******** ******* ******* it is ******* ** note **** individuals *** *** ******* ********** antibodies *** up ** three ****** ** **** ***** ********* ** ** ***** *********** to ****** at this ***** to ******* * ******** ************** *** and **** ***** ** recommended **** * ******** ********** be ********* on ** ***** ** ********* *** eligibility *** ************* *********** ***** ** *** event of ******** ********* ********* *** ******** ****** ******* period *** ************** ** ************ *********** ***** ***** involves *** ************** ** ************** *********** *** * limited ******** has **** ***** ** ****** *** **** ** acquiring HIV infection ***** exposure ******* *********** sex (Dolezal et al ************* ********* **** if *** ****** reports continue ******** ** *********** sex *** the client ******** *** will ******** with *** same ***** ****** ******** **** ** *** * ******** ******* administered after possible ******** *** rather ** ***** ** ***** who *** ** continual high **** of *** ********* ********** new HIV ********** ******** ******* ****** with ******** ******** et ** 2015) ***** a ****** exposure ** ***** ****** ******** **** is *** * ****** ****** ******** ***** of ********* *** infectionsReferencesAshley-Morrow * ********** * Robinson * J ****** * & Smith * (2004) *********** of focus ***** ***** *** ****** ******* ***** type * (HSV-1) *** ***** ********** ***** women ** ten ******* ************ locationsClinical ************ *** infection10(6) ************** * ****** T Giguere * ******* * ******** R * Febo * ***** ***************** * ****** ********* ** ************* prophylaxis (PEP) and pre-exposure *********** ****** ** *** *** ******** is **** ***** *** ******** in ********** **** *** with men ** Boston ********** *** *** ******** ********* *** *************** ************** J * ******* * * ****** * * Dragavon * ****** * * Brennan * * ***** ****** * * ****** *** ******* ** * ************** *********** is antibody ******* ***** **** *************** ********** ************* *********** * ***** Ashley-Morrow * ****** *********** testing *** herpes ******* ***** (HSV)–1 *** ***** ***************** ********** ************************ *********